MRA-3 + MRA-1

Name: Nasal - MRA-3 + MRA-1 25mg / 40mg
SKU: MRA3MRA1n2540
Price: 603.00 USD
Availability: InStock

25mg / 40mg

Nasal/Oral Spray

$603.00

Name:

Metabolic Receptor Agonist-3 / Metaboic Agonist Receptor-1
Sequence*:

Triple Agonist (GLP-1 / GIP / Glucagon) Sequence: H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Aib-Lys-NH₂ (with C20 fatty diacid chain conjugation via linker)
Single Agonist (GLP-1) Sequence: H-Aib-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH
Molecular Formula*:

Triple Agonist (GLP-1 / GIP / Glucagon) Molecular Formula: C₂₈₉H₄₅₂N₇₂O₈₈
Single Agonist (GLP-1) Molecular Formula: C₁₈₇H₂₉₁N₄₅O₅₉
Molecular Weight*:

Triple Agonist (GLP-1 / GIP / Glucagon) Molecular Weight: ≈ 6951.48 g/mol
Single Agonist (GLP-1) Molecular Weight: ≈ 4113.58 g/mol
CAS Registry Number:

Triple Agonist (GLP-1 / GIP / Glucagon) 2381089-83-2
Single Agonist (GLP-1) 910463-68-2

* Typical formulation

MRA-3 + MRA-1 – COMPREHENSIVE RESEARCH PEPTIDE FOR TRIPLE RECEPTOR AND METABOLIC SIGNALING STUDIES

Scientific Overview of MRA-3 + MRA-1

MRA-3 + MRA-1 is a synthetic combined triple-agonist peptide engineered to activate the GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and GCGR (glucagon) receptors simultaneously. It is a next-generation incretin-based analog designed for enhanced receptor engagement, stability, and prolonged activity through fatty acid side-chain acylation.

In in-vitro and in-vivo experimental research, Triple Agonist (GLP-1 / GIP / Glucagon) has been evaluated for its multifaceted receptor interactions and signaling dynamics, focusing on:

• Triple Receptor Co-Activation – examination of concurrent GLP-1R, GIPR, and GCGR binding and second-messenger modulation (Coskun et al., 2023)
• Energy and Metabolic Regulation Pathways – study of combined receptor effects on glucose and lipid metabolism in preclinical models (Shao et al., 2023)
• Peptide Engineering and Acylation Design – analysis of molecular modifications enhancing half-life, receptor specificity, and signal amplitude (Willard et al., 2021)

Triple Agonist (GLP-1 / GIP / Glucagon) is utilized in advanced metabolic and endocrinological research as a tool for understanding poly-agonist mechanisms and integrated receptor signaling across metabolic networks.

*These products are not intended to diagnose, treat, cure, or prevent any disease. Research compounds are sold for laboratory and educational purposes only, not for human or animal use.